Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
about
Clinical imaging characteristics of the positron emission mammography camera: PEM Flex Solo IIEvaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell deathImaging in breast cancer: Single-photon computed tomography and positron-emission tomographyContemporary approaches for imaging skeletal metastasisRadionuclide methods and instrumentation for breast cancer detection and diagnosis.Oncologic positron emission tomography: a surgical perspective.18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysisDiagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomographyRegulation of the Warburg effect in early-passage breast cancer cells.Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer.Positron emission tomography in urologic oncology.Status of lymph node staging.Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue.The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratificationDiagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumabThe role of positron emission tomographic imaging in breast cancer.The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelinesRole of FDG-PET in the diagnosis and treatment of colorectal liver metastases.Positron emission tomography in the staging and management of breast cancer.Characterization of a high-resolution hybrid DOI detector for a dedicated breast PET/CT scannerStratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.The value of FDG positron emission tomography in the management of patients with breast cancer.2-NBDG fluorescence imaging of hypermetabolic circulating tumor cells in mouse xenograft model of breast cancerPET imaging of primary mediastinal tumoursImaging breast cancer response during neoadjuvant systemic therapy.99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection.Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.How should we analyse FDG PET studies for monitoring tumour response?Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patientsStudy of the performance of a novel 1 mm resolution dual-panel PET camera design dedicated to breast cancer imaging using Monte Carlo simulation.Design study of a high-resolution breast-dedicated PET system built from cadmium zinc telluride detectorsThe role of PET/CT for evaluating breast cancer.The vanadyl chelate bis(acetylacetonato)oxovanadium(IV) increases the fractional uptake of 2-(fluorine-18)-2-deoxy-D-glucose by cultured human breast carcinoma cellsIncidental breast lesions identified by 18F-fluorodeoxyglucose-positron emission tomography.Axillary staging in the neoadjuvant setting.Mammography and ultrasonography evaluation of unexpected focal 18F-FDG uptakes in breast on PET/CT.Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.[18F] FDG uptake: pay attention to candies.F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis of pancreatic tumors.
P2860
Q22064556-B489D16E-8757-4BC8-ADA0-F067F9F9FB99Q24648216-FD6E91A2-79A7-4E56-BCEF-6AC6333A2EF7Q24810786-B667A283-8CBA-44C8-8D89-15EE1FFD55CDQ26798170-36299DD8-F053-4566-B6B4-39C2D08513C4Q26823614-771C45A6-5BA8-4AF2-81CC-6A5A285E6B5CQ33945401-5E583A17-FD70-4EAF-8EB5-D0F185C35A72Q34078191-0D4F1972-C6E1-4E46-AAEF-C2A21B46BC69Q34408350-FA65B250-8AC5-4E77-BC5D-20543C1AD9E9Q34594985-19BD77B8-867F-4569-83CC-79F9A8FB391CQ34779799-05B56E85-3891-45C3-ADB6-BFC071D7D7AAQ34849275-7D587AA3-D8E0-4F2D-9E5B-77E448D7145EQ35008175-251D7B45-7A3F-4CCA-95EB-648ECCD12B57Q35042925-8DE668FC-DB49-4B69-BE04-145F62072861Q35093230-83DFFF82-C4DC-417A-B7EC-A4A802F907E7Q35204412-300D2EA3-74BC-45E5-8E31-E2FBDDD6C2EFQ35234716-0A841A80-A798-4847-95FF-9F8899EA2964Q35603895-3259CE2D-662B-4745-91BB-6F0271F154EAQ35697644-345C6D80-E126-4134-A00C-D118D692FB40Q35843694-59055EB7-EB54-4097-9B09-E74E731B204EQ35925299-F783F278-4A4C-4AB5-9197-0BCA18147151Q36097858-8C90A1C4-8FF0-4599-B8E7-A75D4622223AQ36109265-710954D8-9828-4E5E-8CB9-A4D7A62A1C7EQ36116515-8105F81A-12E3-4281-95D6-7CC23B9C226CQ36119176-949E0B93-0760-4E61-9871-95064B135D5DQ36134346-D6BB8335-68B9-48C5-A34F-00368E358A14Q36284526-46B6CCA2-287E-45E6-8797-2EFFAA17C47BQ36294993-6258D34D-EEAB-46E3-97F0-FDF56EB350B8Q36496563-BBD1C027-0B13-4174-B900-766F6B2C363EQ36501282-FAEF3F6F-E56C-4746-BB7F-289815927B03Q36618126-EA2C345A-6713-4DC3-9413-7C9196AB1BDDQ36966166-F4123EE8-B289-41F1-8286-2B63251ACD9DQ36988753-23A764A7-03A4-4B04-BDF9-84106D5A0F53Q37062322-EDAB72C0-F4CB-4204-80DF-A0B0890689C4Q37070763-C0900912-11EA-449D-8D5A-EFB3B8F04834Q37693832-598F4193-0D0F-4874-8BD6-860BE9302B39Q37709210-FD8AD64F-0CE5-492F-825C-160E5A5756E6Q38466284-D81A4200-0F55-480A-96EA-5452AF06E8AAQ38524147-66867B48-EC51-44B1-A5C5-03BBEB3FF279Q39369309-22217EA8-B784-4593-95AD-98564AA2CD5DQ39467787-7E06CF4C-11DA-4B28-BD23-7F399E49E1CD
P2860
Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Primary and metastatic breast ...... -18]-fluoro-2-deoxy-D-glucose.
@en
Primary and metastatic breast ...... -18]-fluoro-2-deoxy-D-glucose.
@nl
type
label
Primary and metastatic breast ...... -18]-fluoro-2-deoxy-D-glucose.
@en
Primary and metastatic breast ...... -18]-fluoro-2-deoxy-D-glucose.
@nl
prefLabel
Primary and metastatic breast ...... -18]-fluoro-2-deoxy-D-glucose.
@en
Primary and metastatic breast ...... -18]-fluoro-2-deoxy-D-glucose.
@nl
P2093
P1433
P1476
Primary and metastatic breast ...... -18]-fluoro-2-deoxy-D-glucose.
@en
P2093
P304
P356
10.1148/RADIOLOGY.179.3.2027989
P407
P577
1991-06-01T00:00:00Z